Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms METEOR-China
- Sponsors AstraZeneca
- 11 Nov 2020 Trial design published in the Trials
- 18 Nov 2019 Primary endpoint (Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period) has been met, according to the results presented at the American Heart Association Scientific Sessions 2019.
- 18 Nov 2019 Results (n=543) presented at the American Heart Association Scientific Sessions 2019.